Reference - PMID:20576575 - Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors.
Reference summary
- PubMed ID
- PMID:20576575
- Title
- Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors.
- Authors
- Argüelles N, Sánchez-Sandoval E, Mendieta A, Villa-Tanaca L, Garduño-Siciliano L, Jiménez F, Cruz Mdel C, Medina-Franco JL, Chamorro-Cevallos G, Tamariz J
- Citation
- Bioorg Med Chem 2010 Jun 15;18(12):4238-48
- Publication year
- 2010
- Abstract
- A series of alpha-asarone-based analogues was designed by conducting docking experiments with published crystal structures of human HMG-CoA reductase. Indeed, synthesis and evaluation of this series showed a highly hypocholesterolemic in vivo activity in a murine model, as predicted by previous docking studies. In agreement with this model, the polar groups attached to the benzene ring could play a key role in the enzyme binding and probably also in its biological activity, mimicking the HMG-moiety of the natural substrate. The hypolipidemic action mechanism of these compounds was investigated by developing a simple, efficient, and novel model for determining HMG-CoA reductase inhibition. The partial purification of the enzyme from Schizosaccharomyces pombe allowed for testing of alpha-asarone- and fibrate-based analogues, resulting in positive and significant inhibitory activity.
